The lack of effect of tunicamycin and 2-deoxy-D-glucose on corneal stromal herpes in rabbits.
A rabbit model for herpes simplex virus (HSV) stromal keratitis, produced by intrastromal injection of live virus, was used to evaluate the effects of tunicamycin and 2-deoxy-D-glucose therapy. In vivo and in vitro evidence suggests that HSV strains that produce stromal disease secrete relatively large amounts of highly antigenic glycoproteins. Also, various studies have shown that tunicamycin and 2-deoxy-D-glucose inhibit the production of complete HSV-specific glycoproteins. Thus, these drugs might be capable of mitigating the clinical manifestations of HSV stromal keratitis by reducing the antigenic load. However, when topical therapy with tunicamycin and/or 2-deoxy-D-glucose was begun in rabbit eyes, the day after intrastromal inoculation of live RE strain HSV and several days before the appearance of stromal disease, no difference in the clinical course of herpetic ocular disease was seen between the experimental (treated) and control (untreated) groups.
D000818:Animals; D000956:Antigens, Viral / Q000096:biosynthesis; D003837:Deoxy Sugars / Q000627:therapeutic use*; D003847:Deoxyglucose / Q000627:therapeutic use*; D005944:Glucosamine / Q000031:analogs & derivatives*; D006023:Glycoproteins / Q000096:biosynthesis / Q000276:immunology; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D011817:Rabbits; D018139:Simplexvirus / Q000378:metabolism; D014415:Tunicamycin / Q000627:therapeutic use*
D000956:Antigens, Viral; D003837:Deoxy Sugars; D006023:Glycoproteins; D014415:Tunicamycin; D003847:Deoxyglucose; D005944:Glucosamine